Cytochrome P450 enzymes: a review on drug metabolizing enzyme inhibition studies in drug discovery and development

Assessment of drug candidate's potential to inhibit cytochrome P450 (CYP) enzymes remains crucial in pharmaceutical drug discovery and development. Both direct and time-dependent inhibition of drug metabolizing CYP enzymes by the concomitant administered drug is the leading cause of drug-drug interactions (DDIs), resulting in the increased toxicity of the victim drug. In this context, pharmaceutical companies have grown increasingly diligent in limiting CYP inhibition liabilities of drug candidates in the early stages and examining risk assessments throughout the drug development process. This review discusses different strategies and decision-making processes for assessing the drug-drug interaction risks by enzyme inhibition and lays particular emphasis on in vitro study designs and interpretation of CYP inhibition data in a stage-appropriate context.

Automated summary

The assessment of drug candidate's potential to inhibit cytochrome P450 (CYP) enzymes is crucial in pharmaceutical drug discovery and development. Pharmaceutical companies are diligent in limiting CYP inhibition liabilities of drug candidates in the early stages to avoid increased toxicity from drug-drug interactions (DDIs), and conducting risk assessments throughout the drug development process.